← Back to Search

Genetic Screening for Cancer

N/A

Waitlist Available

Led By Kenneth Offit, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC.

All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites.

Must not have

MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Summary

This trial is looking at whether there is any link between cancer and genes. It is designed to help create ideas for future research.

Who is the study for?

This trial is for Ashkenazi Jewish individuals with a confirmed cancer diagnosis, including kidney, breast, colon, prostate, lung, ovarian, bladder cancers or lymphoid malignancies. Eligible participants must have donated a blood sample at MSKCC and can have multiple diagnoses of the same cancer type.

What is being tested?

The study is exploring if there's a link between inherited genetic variations (germline polymorphisms) and various cancers using PCR/PCR/LDR strategy to analyze DNA. It aims to generate hypotheses for future research rather than test a treatment.

What are the potential side effects?

Since this trial involves genetic testing without direct medical interventions like drugs or surgery, it does not typically present side effects in the traditional sense as seen with medication or surgical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have cancer in one of the specified organs and have given a blood sample at MSKCC.

Select...

I have had the same type of cancer diagnosed in two or more separate instances.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have a confirmed diagnosis of cancer in specific organs or lymphoma for the AMDeC study part.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: 1Active Control1 Intervention

All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer "cases" and first primary "controls".

Group II: 2Placebo Group1 Intervention

Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.

0 / 3Eligibility criteria met